French pharma giant Sanofi recently opened a pediatric and adult vaccine manufacturing facility on its Toronto campus. The facility officially opened on May 30. According to Sanofi, the new plant significantly increases its capacity to meet growing demand in Canada and around the world for pediatric and adult vaccines for pertussis (whooping cough), diphtheria and…
IDT opens new synthetic biology manufacturing facility
Integrated DNA Technologies (IDT) recently announced the opening of a new 25,000 ft2 plant for synthetic biology products. Proximate to IDT’s flagship U.S. headquarters in Coralville, Iowa, the facility doubles IDT’s synthetic biology footprint, according to a May 28 news release. IDT officials see it furthering the company’s gene synthesis portfolio with differentiated offerings of…
Johnson & Johnson brings in billions from remaining Kenvue stake
Johnson & Johnson has sold off its remaining stake in the Kenvue consumer products business it spun off last year. In a filing with the SEC today, J&J said it brought in $3.6 billion for general corporate purposes from the transaction. Johnson & Johnson brought in the cash on May 15 after it issued a…
Pfizer gives up on Washington state manufacturing plant project
Pfizer recently announced that it will wind down the construction of an Everett, Washington cancer therapies manufacturing plant that it inherited through its $43 billion acquisition of Seagen last year. Over the summer before the acquisition closure in December 2023, Seagen had inked a $215 million deal with contractor Skanksa to build the 270,000-square-foot facility,…
AbbVie president and COO to move into corner office
AbbVie (NYSE: ABBV) recently announced that its board of directors has decided to promote the company’s president and COO Robert A. Michael into the corner office. Michael will succeed Richard A. Gonzalez, who is retiring as CEO on July 1. Gonzalez will stay as executive chair of AbbVie’s board. “On behalf of AbbVie’s board, I…
AbbVie is expanding its Singapore biologics plant
AbbVie (NYSE: ABBV) recently announced that it will spend $223 million to expand its Singapore biologics manufacturing facility. Construction will commence immediately, with the facilities coming online in 2026. The added facilities will create 100 new jobs at the plant, boosting total employment to more than 500 positions in manufacturing, quality assurance, supply chain, engineering…
BD lays off 100 at biotech reagent plant in California
BD recently informed California’s Employment Development Department that it will relocate its Biosciences division’s reagent manufacturing and R&D operations in San Jose. The Life Sciences tech giant is laying off roughly 100 workers due to the relocation to other BD sites, according to its WARN letter dated Dec. 12, 2023. The layoffs have been taking…
Lantheus announces a new CEO
Radiopharmaceutical-focused Lantheus Holdings (NASDAQ: LNTH) announced today that current board chair and industry veteran Brian Markison will become the company’s CEO, effective March 1. Markison succeeds Mary Anne Heino, who is retiring from Lantheus’ corner office after leading the company for nine years. Heino will serve as board chair after March 1. Board member Julie…
Bayer plans significant job cuts as it restructures
Bayer recently announced that it is embarking on a comprehensive restructuring plan with significant staff reductions. The Germany-based pharma giant’s management aims to enhance operational performance through a new model called “Dynamic Shared Ownership” (DSO). This strategic change aims to reduce hierarchies, eliminate bureaucracy, streamline structures, and accelerate decision-making processes. The new model, however, will…
AbbVie launches Produodopa in the EU to treat Parkinson’s
AbbVie (NYSE: ABBV) recently announced the launch of its Parkinson’s disease drug Produodopa (foslevodopa/foscarbidopa) in the European Union. Produodopa is for the treatment of advanced Parkinson’s disease with severe motor fluctuations and hyperkinesia (excessive movement) or dyskinesia (involuntary movement). It’s indicated for use when combinations of Parkinson’s medicinal products have not given satisfactory results. North…